Navigation Links
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Date:10/22/2008

an "adjusted" (or non-GAAP basis) for the three and nine months ended Sept. 30, 2008 and 2007. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with U.S. GAAP.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2007, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we projec
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Avitar Reports Third Quarter Financial Results for Fiscal 2007
3. Martek to Announce Third Quarter 2007 Results on September 5, 2007
4. Third Security, LLC Hires Two New Managing Directors
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. ThirdBiotech Networking Group Launches
7. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
8. PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The Collaborative R&D Terms ... provides comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. , The ... how and why companies enter collaborative R&D deals. ... negotiated deals terms provides critical insight into the ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... MELVILLE, N.Y., July 31 Gentiva Health,Services, ... provider of,comprehensive home health services, today reported strong ... revenues and admissions,in the Company,s Home Health segment., ... for the quarter ended June 29, 2008 included:, ...
... MD (creator of the Hydro-Pulse sinus irrigation device) describes ... anti-inflammatories directly into the sinus cavities using a pulsating ... his patients who experience symptoms of sinus infections, snoring ... ...
... Nektar,Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, August 6, 2008, after the,close of U.S.-based financial ... a conference call to review the results,beginning at 5:00 ... The press release and a live audio-only Webcast of ...
Cached Biology Technology:Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3Gentiva Reports Strong Second Quarter led by Home Health Segment 4Gentiva Reports Strong Second Quarter led by Home Health Segment 5Gentiva Reports Strong Second Quarter led by Home Health Segment 6Gentiva Reports Strong Second Quarter led by Home Health Segment 7Gentiva Reports Strong Second Quarter led by Home Health Segment 8Gentiva Reports Strong Second Quarter led by Home Health Segment 9Gentiva Reports Strong Second Quarter led by Home Health Segment 10Gentiva Reports Strong Second Quarter led by Home Health Segment 11Gentiva Reports Strong Second Quarter led by Home Health Segment 12Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... in German . ... is considered the oldest form of communication. Acting as ... example, the sexual attraction between males and females. Fish ... coordinate reproductive behavior in males and females. Scientists at ... Algarve in Faro, Portugal, and at the Max Planck ...
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... with Staphylococcus aureus bacteria, a leading cause of ... infections, including the antibiotic-resistant strain MRSA. University of ... the immense success of S. aureus the ability to ... to destroy white blood cells. The study was published Nov ...
... are more fattening than others? What about the risks ... for Nutrition (ASN) on December 5-7 for answers to ... in Clinical Nutrition Conference. The 3-day program ... several different satellite sessions, and networking opportunities. Credentialed media, ...
... Nov. 19, 2013   The Bensalem Township Police Department , ... in the field of DNA testing.  This pilot program known ... first of its kind in the country for law enforcement. ... local DNA database with over 6,000 DNA profiles consisting of ...
Cached Biology News:Staphylococcus aureus bacteria turns immune system against itself 2Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... Novagen's frozen Sf9 Insect Cells are derived from ... pretested for optimal growth, use in transfections, plaque ... are frozen in a protocol that optimizes recovery ... for growth in serum-free BacVector Insect Cell Medium ...
Biology Products: